INS and type 1 diabetes mellitus: Moreover, these analyses affirmed both the noninferiority and superiority of insulin icodec relative to the referenced comparators [16–18, 20]. In the ONWARDS 6 trial, which involved individuals with Type 1 diabetes, insulin icodec was found to be noninferior to insulin degludec in terms of A1C reductions during the main phase of the study, from baseline to week [21]. At the end of the extension phase (week 52), a statistically significant greater mean reduction in A1C was observed with insulin icodec compared to degludec.